Elicio Therapeutics (ELTX) Capital Expenditures (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Capital Expenditures came in at $225000.0 in Q1 2026, up 246.1% on a QoQ basis from -$154000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Capital Expenditures (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Capital Expenditures data on file, last reported at $225000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $225000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $241000.0 (down 2.43% YoY) and the FY2025 annual result came in at $16000.0, down 81.61% from the prior year.
- Capital Expenditures advanced to $225000.0 in Q1 2026, from -$154000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2.3 million in Q4 2024 to a low of -$1.0 million in Q2 2024.
- A 5-year average of $15285.7 and a median of -$12000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 19666.67% — and 2024, when it sank 26125.0%.
- Tracing ELTX's Capital Expenditures over 5 years: stood at -$673000.0 in 2022, then jumped by 90.19% to -$66000.0 in 2023, then surged by 3615.15% to $2.3 million in 2024, then plunged by 106.64% to -$154000.0 in 2025, then jumped by 246.1% to $225000.0 in 2026.
- The last three Capital Expenditures figures came in at $225000.0 (Q1 2026), -$154000.0 (Q4 2025), and $170000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | -170,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -170,000.00 |
| Jun 30, 2026 | -170,000.00 |
| Mar 31, 2026 | 225,000.00 |
| Mar 31, 2026 | 225,000.00 |
| Dec 31, 2025 | -154,000.00 |
| Dec 31, 2025 | -154,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Dec 31, 2024 | 2.32 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Mar 31, 2024 | -160,000.00 |
| Mar 31, 2024 | -160,000.00 |
| Dec 31, 2023 | -66,000.00 |
| Dec 31, 2023 | -66,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Sep 30, 2023 | 45,000.00 |